Since T cells expressing CCR4 can respond to chemoatractants (CCL22) secreted by ovarian cancer cells, and CCR4+ Treg have been associated with enhanced tumour recurrence [32], it may be further timely to address the effect of first line treatment on their frequencies. The gene discussed is CCR4; the disease is ovarian cancer.